Vertex Pharmaceuticals (VRTX) Stock Statistics & Valuation Metrics

Vertex Pharmaceuticals has a market cap or net worth of $100.71B. The enterprise value is $110.40B.

Vertex Pharmaceuticals has 256,390,660 shares outstanding. The number of shares has decreased by -2.65% in one year.

Vertex Pharmaceuticals’s return on equity (ROE) is -0.03 and return on invested capital (ROIC) is 2.62%.

The current PE Ratio of Vertex Pharmaceuticals is 27.9. Vertex Pharmaceuticals’s PEG ratio is ―.

In the last 12 months, Vertex Pharmaceuticals had revenue of 11.02B and earned -535.60M in profits. Earnings per share was -2.08.

In the last 12 months, operating cash flow was 3.85B and capital expenditures -346.70M, giving a free cash flow of 3.50B billion.

Vertex Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Vertex Pharmaceuticals upcoming earnings date is Oct 29, 2025, After Close (Confirmed).

Vertex Pharmaceuticals as a current ratio of 2.69, with Debt / Equity ratio of 8.89%

In the past 12 months, Vertex Pharmaceuticals has paid 784.10M in taxes.

Vertex Pharmaceuticals EV to EBITDA ratio is 207.43, with an EV/FCF ratio of -127.64.

Vertex Pharmaceuticals has $6.38B in cash and marketable securities with $1.53B in debt, giving a net cash position of -$4.86B billion.

Gross margin is 86.11%, with operating margin of -2.11%, and net profit margin of -4.86%.

The average price target for Vertex Pharmaceuticals is $491.78, which is 11.43% higher than the current price. The consensus rating is Moderate Buy